Inotiv, Inc.
$0.29
▲
2.42%
2026-04-21 08:27:00
www.inotiv.com
NCM: NOTV
Explore Inotiv, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.46 M
Current Price
$0.29
52W High / Low
$3.32 / $0.22
Stock P/E
—
Book Value
$3.17
Dividend Yield
—
ROCE
-17.26%
ROE
-49.76%
Face Value
—
EPS
$-1.92
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,945
Beta
4.08
Debt / Equity
436.57
Current Ratio
0.3
Quick Ratio
0.27
Forward P/E
-4.58
Price / Sales
0.02
Enterprise Value
$471.12 M
EV / EBITDA
26.64
EV / Revenue
0.92
Rating
None
Target Price
$3.25
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Thermo Fisher Scientific Inc. | $521.21 | 29.42 | $194.29 B | 0.36% | 8.52% | 13.02% | $643.99 / $385.46 | $141.96 |
| 2. | XWELL, Inc. | $1.2 | — | $9.7 M | — | -75.03% | -275.96% | $2.2 / $0.26 | $-1.1 |
| 3. | BillionToOne, Inc. | $86.97 | 489.81 | $3.65 B | — | 2.74% | 2.3% | $138.7 / $61.96 | $10.48 |
| 4. | Quest Diagnostics Incorporated | $200.41 | 22.15 | $22.16 B | 1.76% | 11.16% | 14.75% | $213.5 / $160.02 | $65.18 |
| 5. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
| 6. | Sotera Health Company | $16.28 | 59.4 | $4.63 B | — | 12.01% | 15.42% | $19.85 / $10.17 | $2.13 |
| 7. | Danaher Corporation | $189.21 | 37.67 | $133.79 B | 0.82% | 6.12% | 7.05% | $242.8 / $180.03 | $74.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 120.88 M | 138.14 M | 130.68 M | 124.32 M | 119.88 M | — |
| Operating Profit | -16.14 M | -6.71 M | -5.53 M | -9.48 M | -15.28 M | — |
| Net Profit | -28.38 M | -8.55 M | -17.58 M | -14.87 M | -27.63 M | — |
| EPS in Rs | -0.83 | -0.25 | -0.51 | -0.43 | -0.8 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 513.02 M | 490.74 M | 572.42 M | 547.66 M |
| Operating Profit | -37 M | -54.46 M | -9.24 M | 20.25 M |
| Net Profit | -68.62 M | -108.44 M | -105.14 M | -337.02 M |
| EPS in Rs | -2 | -3.15 | -3.06 | -9.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 771.11 M | 781.36 M | 856.53 M | 962.9 M |
| Total Liabilities | 635.09 M | 610.86 M | 588.04 M | 603.13 M |
| Equity | 136.03 M | 170.5 M | 269.15 M | 360.37 M |
| Current Assets | 194.59 M | 163.41 M | 213.8 M | 232.98 M |
| Current Liabilities | 556.78 M | 119.04 M | 132.19 M | 164.1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.46 M | -6.8 M | 27.88 M | -5.22 M |
| Investing CF | -12.89 M | -16.83 M | -28.75 M | -333.72 M |
| Financing CF | 23.7 M | 9.68 M | 15.87 M | 203.15 M |
| Free CF | -27.07 M | -29.11 M | 0.38 M | -41.52 M |
| Capex | -16.61 M | -22.31 M | -27.5 M | -36.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -14.27% | 4.52% | — | — |
| Earnings Growth % | -3.14% | 68.8% | — | — |
| Profit Margin % | -22.1% | -18.37% | -61.54% | — |
| Operating Margin % | -11.1% | -1.61% | 3.7% | — |
| Gross Margin % | 22.65% | 31.78% | 28.71% | — |
| EBITDA Margin % | -5.45% | -4.63% | -49.93% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.